Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effectiveness and Cost-effectiveness of Ozone Therapy in Patients With Pain Secondary to Chemotherapy-induced Peripheral Neuropathy. Randomized, Triple-blind Clinical Trial (O3NPIQ)

NCT04299893 is registered in ClinicalTrials.gov with Bernardino Clavo, MD, PhD as lead sponsor.

NCT NCT04299893
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04299893 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effectiveness and Cost-effectiveness of Ozone Therapy in Patients With Pain Secondary to Chemotherapy-induced Peripheral Neuropathy. Randomized, Triple-blind Clinical Trial (O3NPIQ)
Lead sponsor
Bernardino Clavo, MD, PhD
Phase
Phase 2/3
Overall status
Recruiting
Start date
November 30, 2020
Completion date
December 31, 2027
Enrollment
42 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy-induced peripheral neuropathy, pain syndrome, pain, neuropathic